



SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Company")

Exercise of Warrants and Total Voting Rights

24 February 2025 - SkinBioTherapeutics plc, (AIM: SBTX, or the "Company"), the life science business focused on skin health, announces that it received an exercise notice for warrants from David Brierwood, following the loan drawdown in October for the acquisition of Bio-Tech Solutions Limited. The proceeds from the exercise of warrants into ordinary shares will be used to reduce the amount of outstanding debt with David Brierwood from £950,000 down to £600,000, as previously announced on 11 October 2024.

Admission and Total Voting Rights

Application has been made for the 3,289,474 new ordinary shares, which will rank pari passu in all respects with the existing ordinary shares of the Company, to be admitted to AIM, which is expected to occur on or around 8.00 a.m. on 25 February 2025 ("Admission"). Upon Admission, the total number of issued shares and the total number of voting rights in the Company will be 231,725,383.

The above figure of 231,725,383 should be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Stuart Ashman, CEO of SkinBioTherapeutics, said:

"We are pleased to continue to have the support of David Brierwood who assisted with the financing for the acquisition of Bio-Tech Solutions last year. This exercise reduces the amount of outstanding debt on the balance sheet, and also the amount of interest the Company pays. The acquisition has proved to be an excellent addition to the Group and performance is in line with expectations. We will update the market in due course with our interim results which will include the financial performance of Bio-Tech Solutions from the date of acquisition through to 31 December 2024."

-Ends-

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.

For more information please contact:

SkinBioTherapeutics plc
Stuart J. Ashman, CEO
Manprit Randhawa, CFO

Tel: +44 (0) 191 495 7325

Cavendish Capital Markets Limited
(Nominated Adviser & Broker)
Giles Balleny, Dan Hodgkinson (Corporate Finance)
Charlie Combe (Broking)
Dale Bellis, Tamar Cranford-Smith (Sales)

Tel: +44 (0) 20 7220 0500

Vigo Consulting (financial press)

Tel: +44 (0) 20 7390 0230

Notes to Editors**About SkinBioTherapeutics plc**

SkinBioTherapeutics is a life science company focused on skin health. The Group's proprietary platform technology, SkinBiotix[®], is based upon discoveries made by the translational dermatology team at the University of Manchester.

The Group's foundation business is targeting the skin healthcare market via five pillars, the most advanced of which are cosmetic skincare (SkinBiotix) and food supplements to modulate the immune system by harnessing the gut-skin axis (AxisBiotix). The cosmetic pillar has a partnership with Croda plc and the Group's first in-house product, AxisBiotix-Ps[™], is a food supplement to address the symptoms of mild to moderate psoriasis.

The Group is also acting as a consolidator and is making acquisitions in complementary areas such as skin care and cosmetic applications, that also bring new distribution and geographical platforms, and manufacturing capabilities through which it can funnel its in-house pillar products.

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit: www.skinbiotherapeutics.com and www.axisbiotix.com.

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as "believe", "could", "should", "envisage", "estimate", "intend", "may", "plan", "potentially", "expect", "will" or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Group's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCFLFIRFLIFFIE